Which has higher valuation & earnings, COAG or MPLT?

Hemab Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A -$24.78 N/A Maplight Therapeutics N/A N/A -$161.15M -$42.31 N/A

Is COAG or MPLT more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Maplight Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Hemab Therapeutics N/A N/A N/A Maplight Therapeutics N/A -98.60% -60.33%

Does the media favor COAG or MPLT?

In the previous week, Maplight Therapeutics had 5 more articles in the media than Hemab Therapeutics. MarketBeat recorded 7 mentions for Maplight Therapeutics and 2 mentions for Hemab Therapeutics. Maplight Therapeutics' average media sentiment score of 1.29 beat Hemab Therapeutics' score of 0.58 indicating that Maplight Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Maplight Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, MPLT or KLRA?

Maplight Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maplight Therapeutics N/A N/A -$161.15M -$42.31 N/A Kailera Therapeutics N/A N/A -$148.96M -$3.65 thousand N/A

Is MPLT or KLRA more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Maplight Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Maplight Therapeutics N/A -98.60% -60.33% Kailera Therapeutics N/A N/A N/A

Does the media refer more to MPLT or KLRA?

In the previous week, Maplight Therapeutics had 1 more articles in the media than Kailera Therapeutics. MarketBeat recorded 7 mentions for Maplight Therapeutics and 6 mentions for Kailera Therapeutics. Maplight Therapeutics' average media sentiment score of 1.29 beat Kailera Therapeutics' score of 0.14 indicating that Maplight Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kailera Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is MESO or MPLT more profitable?

Mesoblast's return on equity of 0.00% beat Maplight Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Mesoblast N/A N/A N/A Maplight Therapeutics N/A -98.60% -60.33%

Does the media prefer MESO or MPLT?

In the previous week, Mesoblast had 2 more articles in the media than Maplight Therapeutics. MarketBeat recorded 9 mentions for Mesoblast and 7 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 1.29 beat Mesoblast's score of 0.33 indicating that Maplight Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Maplight Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MPLT or AUPH?

In the previous week, Aurinia Pharmaceuticals had 3 more articles in the media than Maplight Therapeutics. MarketBeat recorded 10 mentions for Aurinia Pharmaceuticals and 7 mentions for Maplight Therapeutics. Aurinia Pharmaceuticals' average media sentiment score of 1.48 beat Maplight Therapeutics' score of 1.29 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aurinia Pharmaceuticals 9 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MPLT or VCEL?

In the previous week, Maplight Therapeutics had 1 more articles in the media than Vericel. MarketBeat recorded 7 mentions for Maplight Therapeutics and 6 mentions for Vericel. Vericel's average media sentiment score of 1.79 beat Maplight Therapeutics' score of 1.29 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vericel 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Maplight Therapeutics (MPLT) Competitors

$12.60 +0.06 (+0.48%)

As of 08/28/2026 04:00 PM Eastern

Compare

MPLT vs. COAG, KLRA, MESO, AUPH, and VCEL

Should you buy Maplight Therapeutics stock or one of its competitors? Maplight Therapeutics's main competitors and comparable companies include Hemab Therapeutics (COAG), Kailera Therapeutics (KLRA), Mesoblast (MESO), Aurinia Pharmaceuticals (AUPH), and Vericel (VCEL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Maplight Therapeutics compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Maplight Therapeutics (NASDAQ:MPLT) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

In the previous week, Maplight Therapeutics had 5 more articles in the media than Hemab Therapeutics. MarketBeat recorded 7 mentions for Maplight Therapeutics and 2 mentions for Hemab Therapeutics. Maplight Therapeutics' average media sentiment score of 1.29 beat Hemab Therapeutics' score of 0.58 indicating that Maplight Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Maplight Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hemab Therapeutics currently has a consensus target price of $51.40, indicating a potential upside of 14.63%. Maplight Therapeutics has a consensus target price of $29.67, indicating a potential upside of 135.45%. Given Maplight Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Maplight Therapeutics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94

Hemab Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$42.31	N/A

Hemab Therapeutics' return on equity of 0.00% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Maplight Therapeutics	N/A	-98.60%	-60.33%

Summary

Maplight Therapeutics beats Hemab Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Maplight Therapeutics compare to Kailera Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Kailera Therapeutics (NASDAQ:KLRA) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

Maplight Therapeutics currently has a consensus price target of $29.67, suggesting a potential upside of 135.45%. Kailera Therapeutics has a consensus price target of $42.75, suggesting a potential upside of 163.73%. Given Kailera Therapeutics' higher probable upside, analysts plainly believe Kailera Therapeutics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Maplight Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$42.31	N/A
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A

Kailera Therapeutics' return on equity of 0.00% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	-98.60%	-60.33%
Kailera Therapeutics	N/A	N/A	N/A

In the previous week, Maplight Therapeutics had 1 more articles in the media than Kailera Therapeutics. MarketBeat recorded 7 mentions for Maplight Therapeutics and 6 mentions for Kailera Therapeutics. Maplight Therapeutics' average media sentiment score of 1.29 beat Kailera Therapeutics' score of 0.14 indicating that Maplight Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kailera Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Maplight Therapeutics beats Kailera Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Maplight Therapeutics compare to Mesoblast?

Mesoblast (NASDAQ:MESO) and Maplight Therapeutics (NASDAQ:MPLT) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Mesoblast has higher revenue and earnings than Maplight Therapeutics. Mesoblast is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$120.25M	18.84	-$57.50M	-$0.28	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$42.31	N/A

Mesoblast's return on equity of 0.00% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Maplight Therapeutics	N/A	-98.60%	-60.33%

Mesoblast presently has a consensus price target of $39.00, suggesting a potential upside of 123.62%. Maplight Therapeutics has a consensus price target of $29.67, suggesting a potential upside of 135.45%. Given Maplight Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Maplight Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94

In the previous week, Mesoblast had 2 more articles in the media than Maplight Therapeutics. MarketBeat recorded 9 mentions for Mesoblast and 7 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 1.29 beat Mesoblast's score of 0.33 indicating that Maplight Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maplight Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

1.4% of Mesoblast shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Mesoblast beats Maplight Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Maplight Therapeutics compare to Aurinia Pharmaceuticals?

Maplight Therapeutics (NASDAQ:MPLT) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Maplight Therapeutics presently has a consensus target price of $29.67, suggesting a potential upside of 135.45%. Aurinia Pharmaceuticals has a consensus target price of $17.67, suggesting a potential upside of 8.45%. Given Maplight Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Maplight Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

Aurinia Pharmaceuticals has higher revenue and earnings than Maplight Therapeutics. Maplight Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$42.31	N/A
Aurinia Pharmaceuticals	$283.05M	7.66	$287.20M	$2.29	7.11

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Maplight Therapeutics' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	-98.60%	-60.33%
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%

In the previous week, Aurinia Pharmaceuticals had 3 more articles in the media than Maplight Therapeutics. MarketBeat recorded 10 mentions for Aurinia Pharmaceuticals and 7 mentions for Maplight Therapeutics. Aurinia Pharmaceuticals' average media sentiment score of 1.48 beat Maplight Therapeutics' score of 1.29 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aurinia Pharmaceuticals	9 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aurinia Pharmaceuticals beats Maplight Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Maplight Therapeutics compare to Vericel?

Maplight Therapeutics (NASDAQ:MPLT) and Vericel (NASDAQ:VCEL) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

Vericel has a net margin of 7.91% compared to Maplight Therapeutics' net margin of 0.00%. Vericel's return on equity of 6.91% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	-98.60%	-60.33%
Vericel	7.91%	6.91%	5.02%

In the previous week, Maplight Therapeutics had 1 more articles in the media than Vericel. MarketBeat recorded 7 mentions for Maplight Therapeutics and 6 mentions for Vericel. Vericel's average media sentiment score of 1.79 beat Maplight Therapeutics' score of 1.29 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Vericel has higher revenue and earnings than Maplight Therapeutics. Maplight Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$42.31	N/A
Vericel	$276.26M	7.59	$16.52M	$0.47	87.13

Maplight Therapeutics presently has a consensus price target of $29.67, suggesting a potential upside of 135.45%. Vericel has a consensus price target of $58.40, suggesting a potential upside of 42.61%. Given Maplight Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Maplight Therapeutics is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94
Vericel	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Vericel beats Maplight Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Maplight Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MPLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MPLT vs. The Competition

Export

Metric	Maplight Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$584.36M	$3.93B	$7.21B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-0.30	6.75	212.62	21.91
Price / Sales	N/A	1,347.18	625.86	92.63
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	1.25	16.92	11.08	6.36
Net Income	-$161.15M	-$22.74M	$3.48B	$349.79M
7 Day Performance	12.40%	-0.31%	0.13%	-0.80%
1 Month Performance	-10.19%	9.80%	7.08%	4.13%
1 Year Performance	N/A	55.66%	24.67%	15.17%

Maplight Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MPLT Maplight Therapeutics	3.7893 of 5 stars	$12.60 +0.5%	$29.67 +135.4%	N/A	$584.36M	N/A	N/A	109	Positive News
COAG Hemab Therapeutics	3.0008 of 5 stars	$49.19 -0.9%	$51.40 +4.5%	N/A	$2.32B	N/A	N/A	72
KLRA Kailera Therapeutics	2.5321 of 5 stars	$18.44 +3.9%	$42.75 +131.8%	N/A	$2.30B	N/A	N/A	145
MESO Mesoblast	2.4427 of 5 stars	$16.84 -2.0%	N/A	+26.1%	$2.23B	$17.20M	N/A	80	Upcoming Earnings Analyst Forecast
AUPH Aurinia Pharmaceuticals	3.6939 of 5 stars	$16.54 -1.3%	$17.67 +6.8%	+35.9%	$2.23B	$283.05M	7.22	300	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MPLT) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maplight Therapeutics (MPLT) Competitors

MPLT vs. COAG, KLRA, MESO, AUPH, and VCEL

How does Maplight Therapeutics compare to Hemab Therapeutics?

Summary

How does Maplight Therapeutics compare to Kailera Therapeutics?

Summary

How does Maplight Therapeutics compare to Mesoblast?

Summary

How does Maplight Therapeutics compare to Aurinia Pharmaceuticals?

Summary

How does Maplight Therapeutics compare to Vericel?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MPLT vs. The Competition

Maplight Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maplight Therapeutics (MPLT) Competitors

MPLT vs. COAG, KLRA, MESO, AUPH, and VCEL

How does Maplight Therapeutics compare to Hemab Therapeutics?

Does the media favor COAG or MPLT?

Do analysts prefer COAG or MPLT?

Which has higher valuation & earnings, COAG or MPLT?

Is COAG or MPLT more profitable?

Summary

How does Maplight Therapeutics compare to Kailera Therapeutics?

Do analysts recommend MPLT or KLRA?

Which has stronger earnings and valuation, MPLT or KLRA?

Is MPLT or KLRA more profitable?

Does the media refer more to MPLT or KLRA?

Summary

How does Maplight Therapeutics compare to Mesoblast?

Which has higher valuation & earnings, MESO or MPLT?

Is MESO or MPLT more profitable?

Do analysts recommend MESO or MPLT?

Does the media prefer MESO or MPLT?

Do institutionals and insiders believe in MESO or MPLT?

Summary

How does Maplight Therapeutics compare to Aurinia Pharmaceuticals?

Do institutionals & insiders hold more shares of MPLT or AUPH?

Do analysts rate MPLT or AUPH?

Which has preferable valuation and earnings, MPLT or AUPH?

Is MPLT or AUPH more profitable?

Does the media refer more to MPLT or AUPH?

Summary

How does Maplight Therapeutics compare to Vericel?

Is MPLT or VCEL more profitable?

Does the media prefer MPLT or VCEL?

Which has higher earnings & valuation, MPLT or VCEL?

Do analysts rate MPLT or VCEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MPLT vs. The Competition

Maplight Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools